Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteome of Erythropoietin-induced mouse CFU-E cells

ABSTRACT: Time-resolved CFU-E proteome was analyzed by time collapsed super-SILAC with erythropoietin-stimulated BaF3-mEpoR proteome as internal heavy standard.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Embryo, Liver, Erythroid Progenitor Cell

SUBMITTER: Alexander Held

LAB HEAD: Marcel Schilling

PROVIDER: PXD004539 | Pride | 2022-09-28

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Publications

Erythropoietin-driven dynamic proteome adaptations during erythropoiesis prevent iron overload in the developing embryo.

Chakraborty Sajib S Andrieux Geoffroy G Kastl Philipp P Adlung Lorenz L Altamura Sandro S Boehm Martin E ME Schwarzmüller Luisa E LE Abdullah Yomn Y Wagner Marie-Christine MC Helm Barbara B Gröne Hermann-Josef HJ Lehmann Wolf D WD Boerries Melanie M Busch Hauke H Muckenthaler Martina U MU Schilling Marcel M Klingmüller Ursula U

Cell reports 20220901 12

Erythropoietin (Epo) ensures survival and proliferation of colony-forming unit erythroid (CFU-E) progenitor cells and their differentiation to hemoglobin-containing mature erythrocytes. A lack of Epo-induced responses causes embryonic lethality, but mechanisms regulating the dynamic communication of cellular alterations to the organismal level remain unresolved. By time-resolved transcriptomics and proteomics, we show that Epo induces in CFU-E cells a gradual transition from proliferation signat ...[more]

PMID: 36130519

Similar Datasets

Protein abundance of AKT and ERK pathway components governs cell-type-specific regulation of proliferation

Project description:Signaling through the AKT and ERK pathways controls cell proliferation. However, the integrated regulation of this multistep process, involving signal processing, cell growth and cell-cycle progression, is poorly understood. Here we study different murine hematopoietic cell types, in which AKT and ERK signaling is triggered by erythropoietin (Epo). Although these cell types share the molecular network topology for pro-proliferative Epo signaling, they exhibit distinct proliferative responses. Iterating quantitative experiments and mathematical modeling, we identify two molecular sources for cell-type-specific proliferation. First, cell-type-specific protein abundance patterns cause differential signal flow along the AKT and ERK pathways. Second, downstream regulators of both pathways have differential effects on proliferation, suggesting that protein synthesis is rate-limiting for faster-cycling cells while slower cell-cycles are controlled at the G1-S progression. The integrated mathematical model of Epo-driven proliferation explains cell-type-specific effects of targeted AKT and ERK inhibitors and faithfully predicts based on the protein abundance anti-proliferative effects of inhibitors in primary human erythroid progenitor cells. Our findings suggest that the effectiveness of targeted cancer therapy might become predictable from protein abundance patterns.

2017-01-30 | PXD004816 | Pride

Proteome of BaF3-mEpoR cells stimulated with 5 U/ml Epo, 10 ng/ml IL-3 or left untreated

Project description:The proteome of BaF3-mEpoR cells stimulated with 5 U/ml Epo, 10 ng/ml IL-3 or left untreated were analyzed by label free LC-MS/MS.

2022-09-28 | PXD035181 | Pride

Analysis of mouse T cell transcription profile after co-culture with BaF3 cells with or without the oncogenic point mutation JAK2 V617F

Project description:The activation of PD-1 (Programmed Death receptor-1) on T cells can cause T cell exhaustion and immune tolerance. Some tumors up-regulate the expression of the ligand of PD-1, namely PD-L1 (Programmed Death Receptor-Ligand 1), thus preventing anti-tumor immune response and promoting immune-escape. Previous studies have shown that JAK2 (Janus Kinase 2) signaling can promote PD-L1 expression in Hodgkin Lymphoma. In Myeloproliferative Neoplasms (MPN), JAK2 is frequently characterized by the the presence of the point-mutation V617F, which leads to its constitutive activation and to uncontrolled cell proliferation and survival. Accordingly, tumor cell lines expressing JAK2 V617F express higher levels of PD-L1 as compared to tumor cell lines negative for such mutations. In this experiment, we transfected BaF3 cells with a vector (plasmid for Murine Stem Cell Virus) containing the gene for JAK2 with the point-mutation V617F. As control, we used BaF3 cells transfected with the same vector, but without the gene for JAK2 V617F (empty vector). Both the cell lines (with/without JAK2 V617F) were co-cultured with primary murine T cells. When co-cultured with BaF3 cells expressing JAK2 V617F, T cells upregulated genes connected to senescence pathways, showed increased apoptosis, less cytokine production, and displayed other forms of dysfunction which can be associated with the activation of PD-1.

2018-12-01 | E-MTAB-5028 | biostudies-arrayexpress

Humoral Immune response of Galleria mellonella to BCG and APP

Project description:The humoral immune response of Galleria mellonella exposed to Mycobacterium bovis BCG (vaccine strain), 1x107 CFU (10 ul inoculum) were injected into the larvae. For low dose BCG challenge, 1x105 CFU (10 ul) were injected. For larval challenge with Actinobacillus pleuropneumoniae (APP), ~1.5x106 CFU (10 ul) were injected. APP were only challenged at this single dose. For larval challenge with Control (0h) were included. APP and low dose (1x105 CFU) BCG were sampled only at 48 h post infection.

2021-09-08 | PXD015250 | Pride

Phosphoproteomics analysis of normal and mutated granulocyte colony stimulating factor receptors

Project description:Granulocyte colony stimulating factor receptor (G-CSFR) plays important role in the production of neutrophils from hematopoietic stem cells. Mutated form of the receptor has been directly associated with two distinct malignant phenotype in patients, e.g. acute myeloid leukemia (AML) and chronic neutrophilic leukemia (CNL). However, the signaling mechanism of the mutated G-CSFRs is not well understood. Here, we describe a comprehensive SILAC based quantitative phosphoproteomic analysis of the mutated G-CSFRs compared to the normal receptor using BaF3 cell line based in vitro model system. High pH reversed phase concatenation and Titanium Dioxide Spin Tip column were utilized to increase the dynamic range and detection of the phosphoproteome of G-CSFRs. The dataset was further analyzed using several computational and bioinformatics tools. Overall, this dataset is a first of any phosphoproteomics analysis of granulocyte colony stimulating factor receptors in the normal and disease associated mutations. We anticipate that our dataset will have a strong potential to decipher the phospho-signaling differences between the normal and malignant G-CSFR biology with therapeutic implications.

2019-02-14 | PXD009311 | Pride

Gene expression profile of Baf3 cells conditionally expressing BCR-ABL in presence and absence of Growth factor IL-3

Project description:The Baf3 are dependent on IL-3 for grwoth however transformation by BCR -ABL oncogene causes BAf3 cells independent of IL-3. The BAf3 cells expressing BCR-ABL are dependent on continuous expression of BCR_ABL for growth. Inhibitionof BCR-ABL by its inhibitor Imatinib cause these cells to undergo apoptosis. When these cells are grown with IL-3 these cells do not respond to Imatinib mediated grwoth arrest.

2017-03-20 | GSE75057 | GEO

HIF-1synergizes with glucocorticoids to promote BFU-E progenitor self-renewal

Project description:With the aim of finding small molecules that stimulate erythropoiesis earlier than erythropoietin and that enhance CFU-E production, we studied the mechanism by which glucocorticoids increase CFU-E formation. Using BFU-E and CFU-E progenitors purified by a new technique, we demonstrate that glucocorticoids stimulate the earliest (BFU-E) progenitors to undergo limited self-renewal, which increases formation of CFU-E cells > 20-fold. Interestingly, glucocorticoids induce expression of genes in BFU-E cells that contain promoter regions highly enriched for hypoxia-induced factor 1 alpha (HIF1a) binding sites. This suggests activation of HIF1a may enhance or replace the effect of glucocorticoids on BFU-E self-renewal. Indeed, HIF1a activation by a prolyl hydroxylase inhibitor (PHI) synergizes with glucocorticoids and enhances production of CFU-Es 170-fold. Since PHIs are able to increase erythroblast production at very low concentrations of glucocorticoids, PHI-induced stimulation of BFU-E progenitors thus represents a conceptually new therapeutic window for treating Epo-resistant anemia. RNA-Seq was performed on enriched populations of BFU-E, CFU-E and Ter119+ as well as BFU-E enriched cells treated with Dex and DMOG

2010-12-21 | E-GEOD-26086 | biostudies-arrayexpress

JAK2 Naive and Persitent Murine BaF3 cells infected with MPLW515L

Project description:Transcriptional profiling of Murine BaF3 cells infected with MPLW515L grown under either normal conditions (Naive) or in 0.8 uM INCB18424 for 4-6 weeks (Persistent). Naive and Persistent cells were then treated with either DMSO (Control) or 0.8 uM INCB18424 for 4 hours. Goal was to determine transcriptional changes conditioned upon sensitivity/resistance of BaF3 MPLW515L mutants to JAK1/2 specific inhibitor.

2012-05-31 | GSE38335 | GEO

mRNA expression quantitative Analysis of BaF3-T315I cell lines treated with I13 compared with control

Project description:The goals of this study are to evaluate the mRNA expressions of genes in BaF3-T315I cell lines treated with I13

2023-04-03 | GSE225777 | GEO

the mRNA expression quantitative Analysis of K562 and BaF3-T315I treated with JOA compared with control.

Project description:The goals of this study are toevaluate the mRNA expressions of genes in K562 and BaF3-T315I cell lines treated with JOA

2023-01-19 | GSE209939 | GEO